8-K: Pulmatrix and MannKind Forge Cross-Licensing Deal, Pulmatrix Transfers R&D Facility

Pulmatrix and MannKind have entered into a cross-licensing agreement involving Pulmatrix's iSPERSE technology and MannKind's Cricket inhalation device, with Pulmatrix transferring its R&D facility to MannKind.

Summary

• Pulmatrix and MannKind have agreed to a cross-licensing deal where Pulmatrix will transfer its Bedford, Massachusetts R&D facility to MannKind.
• MannKind will assume Pulmatrix's lease obligations for the facility.
• Pulmatrix grants MannKind exclusive licenses for iSPERSE formulations of Clofazimine, treatments for nontuberculous mycobacteria lung disease, and insulin.
• Pulmatrix also grants MannKind non-exclusive licenses for iSPERSE formulations for endocrine and interstitial lung diseases.
• MannKind grants Pulmatrix an exclusive license for its Cricket device for the delivery of dihydroergotamine (DHE), including Pulmatrix's PUR3100 treatment for acute migraine.
• MannKind also grants Pulmatrix a non-exclusive license for the Cricket device for neurological disease treatments.
• MannKind will provide dry powder drug formulation development services to Pulmatrix.
• The transfer of the R&D facility is expected to close in July 2024.

Sentiment

Score: 7

Explanation: The document indicates a positive strategic move for Pulmatrix, extending its cash runway and validating its technology. The cross-licensing agreement with MannKind is a positive development, but the transfer of the R&D facility could be seen as a potential loss of internal capabilities.

Positives

• The deal extends Pulmatrix's cash runway further into 2026.
• The agreement validates the potential of Pulmatrix's iSPERSE technology.
• Pulmatrix gains access to MannKind's Cricket device for its PUR3100 migraine treatment.
• MannKind will provide development services to Pulmatrix, supporting the development of dry powder formulations.
• The cross-licensing agreement is royalty-free and perpetual.

Negatives

• Pulmatrix is transferring its R&D facility, which could impact its internal research capabilities.
• Pulmatrix is granting exclusive licenses for its iSPERSE technology in certain therapeutic areas to MannKind.

Risks

• The closing of the transaction is subject to customary conditions and may not occur as expected.
• The success of the licensed technologies and products is not guaranteed.
• There are risks associated with the development and commercialization of new pharmaceutical products.
• The company's ability to raise capital in the future is not guaranteed.

Future Outlook

The company anticipates closing the transactions in July 2024 and expects the agreement to support the development of PUR3100 and its potential application with MannKind's Cricket device.

Management Comments

• Ted Raad, Chief Executive Officer of Pulmatrix, commented, MannKind's interest in iSPERSE validates the enablement potential of our innovative particle engineering dry powder technology.
• Ted Raad also stated, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026.
• Ted Raad also stated, We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind's Cricket device to develop the 1st orally inhaled DHE treatment for acute migraine.

Industry Context

This agreement reflects a trend in the pharmaceutical industry towards strategic collaborations and cross-licensing to leverage complementary technologies and resources. It also highlights the growing interest in inhaled drug delivery systems for various therapeutic areas.

Comparison to Industry Standards

• Cross-licensing agreements are common in the pharmaceutical industry, allowing companies to access and utilize each other's technologies and intellectual property.
• The transfer of a research facility is less common but can be a strategic move to reduce costs and focus on core competencies.
• The agreement between Pulmatrix and MannKind is similar to other deals where companies with complementary technologies collaborate to develop new products.
• For example, other companies have entered into similar agreements to combine drug formulations with delivery devices.

Stakeholder Impact

• Shareholders may view the agreement positively due to the extended cash runway and validation of Pulmatrix's technology.
• Employees at the Bedford facility may be impacted by the transfer to MannKind, with some potentially being hired by MannKind.
• Customers may benefit from the development of new inhaled therapies.
• Suppliers may see changes in their relationships with Pulmatrix and MannKind.

Next Steps

• The companies will work to close the transactions in July 2024.
• MannKind will assume the lease of the Bedford, MA facility.
• MannKind will begin providing development services to Pulmatrix.
• Pulmatrix will continue to develop PUR3100 for acute migraine.

Key Dates

Keywords

iSPERSE, MannKind, Pulmatrix, Cricket device, Cross-licensing, R&D facility, Dihydroergotamine, PUR3100, Inhaled therapies, Dry powder, Clofazimine, Insulin, Migraine, Neurological disease, Nontuberculous mycobacteria